Current Opinion in Pharmacology最新文献

Ivermectin and non-parasitic disorders: An update. 伊维菌素和非寄生虫疾病：最新进展。

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2025-09-16 DOI: 10.1016/j.coph.2025.102574

Behdad Seyyedabadi, Shabnam Babataheri, Marziyeh Naseri, Ismail Laher, Hamid Soraya

{"title":"Ivermectin and non-parasitic disorders: An update.","authors":"Behdad Seyyedabadi, Shabnam Babataheri, Marziyeh Naseri, Ismail Laher, Hamid Soraya","doi":"10.1016/j.coph.2025.102574","DOIUrl":"https://doi.org/10.1016/j.coph.2025.102574","url":null,"abstract":"<p><p>Ivermectin, a broad-spectrum anti-parasitic agent, demonstrates potential therapeutic benefits in treating non-parasitic ailments, particularly in neurological, respiratory, inflammatory, dermal, cardiovascular, and neoplastic disorders. For instance, ivermectin targets both DNA and RNA viruses, inhibits angiogenesis, and has anti-cancer properties, which result from inhibiting RNA helicase, inducing mitochondrial dysfunction, apoptosis, necrosis, and autophagy, as well as promoting oxidative stress. While the precise neurological impacts of ivermectin are not fully understood, it also has anticonvulsant properties in rats. Recent discoveries have revealed the neuroprotective effects of ivermectin in cerebral ischemia/reperfusion and Alzheimer's disease. Although there is limited research on the influence of ivermectin on the cardiovascular system, some studies have reported cardioprotective effects of ivermectin. However, a recent study suggested that ivermectin pre-treatment may have detrimental effects on myocardial ischemia. Consequently, numerous questions regarding the therapeutic/adverse effects of ivermectin remain unanswered and necessitate further investigation. We review the effects of ivermectin in non-parasitic diseases with an emphasis on current research in this field.</p>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"85 ","pages":"102574"},"PeriodicalIF":4.2,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modulating neuroinflammation through electroacupuncture: Mechanistic insights and pharmacological synergies 通过电针调节神经炎症：机制见解和药理学协同作用

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2025-09-04 DOI: 10.1016/j.coph.2025.102564

Salvador Quiroz-González , Erika Elizabeth Rodríguez-Torres , Ismael Jiménez-Estrada

{"title":"Modulating neuroinflammation through electroacupuncture: Mechanistic insights and pharmacological synergies","authors":"Salvador Quiroz-González , Erika Elizabeth Rodríguez-Torres , Ismael Jiménez-Estrada","doi":"10.1016/j.coph.2025.102564","DOIUrl":"10.1016/j.coph.2025.102564","url":null,"abstract":"<div><div>Neuroinflammation plays a central role in the pathogenesis of numerous neurological and neurodegenerative diseases, driven by complex interactions among glial activation, cytokine release, blood–brain barrier (BBB) dysfunction, and autonomic dysregulation. While pharmacological therapies targeting inflammatory mediators show promise, their efficacy is often limited by poor BBB permeability and systemic side effects. Electroacupuncture (EA), a neuromodulatory technique that combines acupuncture with electrical stimulation, has emerged as a promising adjunctive intervention for modulating neuroimmune dynamics. EA activates defined somatosensory afferents and transmits signals to key autonomic and limbic nuclei, including the brainstem and hypothalamus, which regulate immune responses. At the molecular level, EA suppresses pro-inflammatory pathways such as TLR4/NF- κB and NLRP3 inflammasome activation while promoting anti-inflammatory signaling via the JAK2/STAT3 and PI3K/Akt pathways. It also influences microglial polarization toward the reparative M2 phenotype and modulates BBB permeability and gut–brain axis interactions. Notably, EA has demonstrated synergistic potential when combined with pharmacologic agents such as <span>l</span>-DOPA, selegiline, donepezil, and minocycline, enhancing neuroprotective efficacy and reducing inflammatory and oxidative burdens. This highlights EA's potential integration into clinical strategies for treating neurodegenerative disorders. Understanding the neural circuits and immunological cascades engaged by EA may inform its future integration with pharmacotherapy in personalized neuroimmune interventions.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"85 ","pages":"Article 102564"},"PeriodicalIF":4.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacoutilization data-driven artificial intelligence–assisted diagnosis algorithm to improve the pharmacological treatment of pain and agitation in patients suffering from severe dementia 药物利用数据驱动的人工智能辅助诊断算法改善重度痴呆患者疼痛和躁动的药物治疗

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2025-07-28 DOI: 10.1016/j.coph.2025.102563

Damiana Scuteri , Carlo Adornetto , Gianluigi Greco , Pierluigi Nicotera , Giacinto Bagetta , Maria Tiziana Corasaniti

{"title":"Pharmacoutilization data-driven artificial intelligence–assisted diagnosis algorithm to improve the pharmacological treatment of pain and agitation in patients suffering from severe dementia","authors":"Damiana Scuteri , Carlo Adornetto , Gianluigi Greco , Pierluigi Nicotera , Giacinto Bagetta , Maria Tiziana Corasaniti","doi":"10.1016/j.coph.2025.102563","DOIUrl":"10.1016/j.coph.2025.102563","url":null,"abstract":"<div><div>The number of diagnoses and drug prescriptions for dementia patients is poorly available. Delay in the diagnosis of Alzheimer's disease (AD), for which missed diagnoses amount to over half cases, and undertreatment of chronic and neuropathic pain mirroring excessive use of harmful antipsychotics and antidepressants is reported. Our study aimed at diagnosing AD through the most advanced artificial intelligence (AI) methodologies even in patients who escaped clinical observation. To this end, pharmacoepidemiology data collected as part of the first retrospective community study in a wide sample of 298,000 individuals, 84,235 aged over 60 years, were used to set up an AI algorithm for the rescue of missed diagnoses of AD. The core of the algorithm consisted in the management of time series represented by pharmacological therapies through a distance matrix and in the use of autoencoders. Patients without a diagnosis of AD based on pharmacotherapy were 114.920, while diagnosed patients were 1.150, mainly aged between 75 and 84 years, pointing at late start of treatment. Increased use of antidepressants, neuroleptics, and mood stabilizers is found in patients treated with acetylcholinesterase inhibitors (AChEIs) and memantine, while nonsteroidal anti-inflammatory drugs, paracetamol–codeine and opioids are mostly prescribed to patients not receiving AChEIs and memantine. The classification model demonstrated good global accuracy at the end of training, equal to 79.12%. Further studies and longitudinal monitoring of patients are needed to improve disease detection and management. The deep learning–based pharmacoutilization algorithm generated in the present study will aid the diagnosis of AD and the understanding of neuropsychiatric symptoms treatment.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"84 ","pages":"Article 102563"},"PeriodicalIF":4.2,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144831161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “From “contraindicated” to “first line” – Current mechanistic insights beyond canonical β-receptor signaling” [COPHAR 76 (2024) 102458] “从“禁忌症”到“一线”-目前超越标准β受体信号传导的机制见解”的更正[COPHAR 76 (2024) 102458]

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2025-07-19 DOI: 10.1016/j.coph.2025.102550

Theresa Brand , Ann-Kathrin Lukannek , Valérie Jahns , Roland Jahns , Kristina Lorenz

引用次数: 0

Corrigendum to “Challenges in formulating transdermal systems for treating chronic skin infections” [Curr Opin Pharmacol 83 (2025) 102540] “制定治疗慢性皮肤感染的透皮系统所面临的挑战”的勘误表[现行药物管理83 (2025)102540]

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2025-07-16 DOI: 10.1016/j.coph.2025.102554

Akshay Ramchandra Yadav , Shital Aniket Shinde , Shubhangi B. Sutar , Snehal Aditya Arvindekar , Dwi Marlina Syukri

引用次数: 0

Recent innovations in clinical trial design for inflammatory bowel disease 炎症性肠病临床试验设计的最新创新

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2025-07-05 DOI: 10.1016/j.coph.2025.102551

Rocio Sedano , Christopher Ma , Vipul Jairath

{"title":"Recent innovations in clinical trial design for inflammatory bowel disease","authors":"Rocio Sedano , Christopher Ma , Vipul Jairath","doi":"10.1016/j.coph.2025.102551","DOIUrl":"10.1016/j.coph.2025.102551","url":null,"abstract":"<div><div>Clinical trial design in inflammatory bowel disease (IBD) is evolving to address challenges in drug development and approvals. For clinical development, notable innovations include Bayesian designs, adaptive designs, integrated-phase trials and master protocols (such as umbrella, basket, and platform trials). The inclusion of biomarker-driven strategies and precision medicine (PM) trials bring aim to enable patient stratification based on prognostic or predictive markers, leveraging molecular signatures to customize therapy. However, recent studies highlight both the promise and complexity of this approach. Patient-reported outcomes (PROs) have gained prominence as key endpoints, aligning trials with patient-centric measures and regulatory guidance that emphasize symptoms and quality-of-life metrics. Digital health tools and artificial intelligence (AI) are being integrated to streamline trial conduct, from remote monitoring and telemedicine visits to AI-assisted recruitment and data analysis. Pragmatic trials and the integration of real-world evidence (RWE) aim to complement traditional efficacy trials by evaluating treatments in routine care settings. Together, these innovations mark a new era in IBD clinical trial design, aiming to expedite therapeutic development and enhance the relevance of trials to patient care.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"84 ","pages":"Article 102551"},"PeriodicalIF":4.2,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144738541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Smart solutions for tough infections: The rise of next-gen transdermal drug delivery 针对严重感染的智能解决方案：新一代经皮给药技术的兴起

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2025-07-03 DOI: 10.1016/j.coph.2025.102552

Sachin S. Mali, Prakash D. Jadhav, Sameer J. Nadaf

引用次数: 0

Molecular insights driving personalized therapies 分子洞察推动个性化治疗

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2025-07-02 DOI: 10.1016/j.coph.2025.102553

Kristina Lorenz, Jürgen Schrader

引用次数: 0

Ionic liquid choline and geranic acid-mediated topical drug delivery in skin tissue regeneration and neutralization of potential pathogens: A review 离子液体胆碱和天竺葵酸介导的局部药物递送在皮肤组织再生和潜在病原体中和中的研究进展

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2025-06-25 DOI: 10.1016/j.coph.2025.102549

Popat Mohite , Shubham Munde , Aarati Budar , Sudarshan Singh , Chuda Chittasupho

引用次数: 0

Nanotechnology-enhanced transdermal systems for infectious diseases 纳米技术增强的传染病透皮系统

IF 4 3区医学

Current Opinion in Pharmacology Pub Date : 2025-06-20 DOI: 10.1016/j.coph.2025.102547

Swati Udugade , Babaso V. Udugade , Sanket R. Patil , Ashwini C. Utage , Shagun Swaroop

引用次数: 0